Loomis, Sayles & Company
HZNP

Loomis, Sayles & Company’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Loomis, Sayles & Company’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,591
Closed -$222K – 1023
2022
Q3 		$222K Sell
3,591
-255,525
-99% -$17.9M ﹤0.01% 462
2022
Q2 		$20.7M Sell
259,116
-90,470
-26% -$8.57M 0.04% 241
2022
Q1 		$36.8M Buy
349,586
+11,054
+3% +$1.08M 0.05% 187
2021
Q4 		$36.5M Sell
338,532
-3,433
-1% -$375K 0.04% 226
2021
Q3 		$37.5M Buy
341,965
+9,730
+3% +$1.01M 0.05% 214
2021
Q2 		$31.1M Buy
332,235
+12,508
+4% +$1.15M 0.04% 243
2021
Q1 		$29.4M Sell
319,727
-18,168
-5% -$1.53M 0.04% 235
2020
Q4 		$24.7M Sell
337,895
-1,752
-0.5% -$130K 0.03% 234
2020
Q3 		$26.4M Sell
339,647
-151,904
-31% -$10.5M 0.04% 186
2020
Q2 		$27.3M Sell
491,551
-912,729
-65% -$39M 0.04% 173
2020
Q1 		$41.6M Buy
1,404,280
+852
+0.1% +$28.8K 0.09% 87
2019
Q4 		$50.8M Sell
1,403,428
-37,734
-3% -$1.16M 0.09% 91
2019
Q3 		$39.2M Buy
1,441,162
+255,461
+22% +$6.61M 0.08% 108
2019
Q2 		$28.5M Buy
1,185,701
+19,468
+2% +$494K 0.05% 154
2019
Q1 		$30.8M Buy
1,166,233
+378,138
+48% +$8.96M 0.06% 130
2018
Q4 		$15.4M Buy
788,095
+786,314
+44,150% +$15.4M 0.04% 216
2018
Q3 		$35K Sell
1,781
-349
-16% -$6.63K ﹤0.01% 638
2018
Q2 		$35K Sell
2,130
-259
-11% -$3.95K ﹤0.01% 669
2018
Q1 		$34K Buy
+2,389
New +$35.3K ﹤0.01% 673

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Loomis, Sayles & Company's HZNP Position: Q4 2022 in Review

Loomis, Sayles & Company sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 3,591 shares — an estimated $222K sold.

Loomis, Sayles & Company first reported a position in HZNP in Q1 2018 and held it in 19 quarters. The position peaked at $50.8M in Q4 2019. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

  • Loomis, Sayles & Company reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 3,591 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $222K.
  • Loomis, Sayles & Company first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and held it in 19 quarters.
  • Loomis, Sayles & Company's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $50.8M in Q4 2019.
  • 615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Loomis, Sayles & Company's 13F filing for Q4 2022, filed 10 Feb 2023.